Bridgewater Associates LP raised its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) by 10.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,494 shares of the medical device company’s stock after purchasing an additional 9,244 shares during the quarter. Bridgewater Associates LP owned about 0.16% of Tandem Diabetes Care worth $6,007,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of TNDM. Arizona State Retirement System increased its stake in Tandem Diabetes Care by 1.2% during the 1st quarter. Arizona State Retirement System now owns 17,174 shares of the medical device company’s stock valued at $1,997,000 after purchasing an additional 210 shares in the last quarter. Versor Investments LP increased its stake in Tandem Diabetes Care by 161.5% during the 1st quarter. Versor Investments LP now owns 3,700 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 2,285 shares in the last quarter. Shell Asset Management Co. acquired a new position in Tandem Diabetes Care during the 1st quarter valued at approximately $326,000. Ausdal Financial Partners Inc. increased its stake in Tandem Diabetes Care by 11.1% during the 1st quarter. Ausdal Financial Partners Inc. now owns 6,119 shares of the medical device company’s stock valued at $712,000 after purchasing an additional 610 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Tandem Diabetes Care by 26.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 17,061 shares of the medical device company’s stock valued at $1,984,000 after purchasing an additional 3,574 shares in the last quarter. Institutional investors and hedge funds own 95.28% of the company’s stock.
Tandem Diabetes Care Stock Performance
Shares of TNDM stock opened at $39.55 on Thursday. The company has a quick ratio of 4.20, a current ratio of 4.81 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $48.19 and a two-hundred day moving average of $55.47. Tandem Diabetes Care, Inc. has a 1-year low of $33.51 and a 1-year high of $155.86.
Wall Street Analysts Forecast Growth
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.